Myles David C.'s Form 4 filing
Olema Pharmaceuticals, Inc. (OLMA) · filed Dec 11, 2024
- Accession no.
- 0001415889-24-029027
- Filed
- Dec 11, 2024
- Trade date
- Dec 9-11, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $234.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Myles David C.CIK 0001831216 | Officer (CH. DISCOV. & NON-CLIN DEV OFF) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 9, 2024 | Common Stock | AGrant or awardAcquired | +48,750 | $0.00 | $0 | 624,399 | Direct | |
| Dec 10, 2024 | Common Stock | SSaleDisposed | −12,452 | $9.38 | −$116,799.76 | 611,947 | Direct | |
| Dec 11, 2024 | Common Stock | SSaleDisposed | −13,314 | $8.66 | −$115,299.24 | 598,633 | Direct | |
| Dec 11, 2024 | Common Stock | SSaleDisposed | −300 | $9.39 | −$2,817 | 598,333 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.